Shares of Envista Holdings Corporation (NYSE:NVST – Get Free Report) have earned an average recommendation of “Moderate Buy” from the sixteen research firms that are currently covering the stock, MarketBeat reports. Nine investment analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $29.3077.
Several analysts have commented on the stock. Piper Sandler reaffirmed a “neutral” rating and issued a $28.00 price objective (up from $26.00) on shares of Envista in a research report on Thursday, August 6th. Wall Street Zen upgraded Envista from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Weiss Ratings upgraded Envista from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, August 6th. Mizuho set a $29.00 price target on shares of Envista in a report on Thursday, August 6th. Finally, BMO Capital Markets assumed coverage on shares of Envista in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $27.00 price objective for the company.
Check Out Our Latest Stock Analysis on Envista
Insiders Place Their Bets
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in NVST. GSA Capital Partners LLP purchased a new stake in shares of Envista in the 2nd quarter valued at about $2,039,000. Dimensional Fund Advisors LP increased its position in shares of Envista by 1.6% in the first quarter. Dimensional Fund Advisors LP now owns 9,780,948 shares of the company’s stock worth $248,130,000 after purchasing an additional 152,488 shares during the last quarter. Pzena Investment Management LLC bought a new position in shares of Envista in the second quarter worth approximately $30,494,000. SummitTX Capital L.P. purchased a new stake in Envista in the first quarter valued at approximately $4,268,000. Finally, Principal Financial Group Inc. raised its stake in Envista by 36.8% in the first quarter. Principal Financial Group Inc. now owns 483,983 shares of the company’s stock valued at $12,279,000 after purchasing an additional 130,237 shares in the last quarter.
Envista Price Performance
Envista stock opened at $27.34 on Friday. Envista has a 52 week low of $18.77 and a 52 week high of $30.42. The company’s 50 day moving average price is $26.95 and its two-hundred day moving average price is $26.33. The stock has a market cap of $4.39 billion, a P/E ratio of 47.15, a P/E/G ratio of 1.30 and a beta of 0.86. The company has a quick ratio of 2.07, a current ratio of 2.43 and a debt-to-equity ratio of 0.47.
Envista (NYSE:NVST – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.07. The company had revenue of $730.50 million during the quarter, compared to the consensus estimate of $716.11 million. Envista had a return on equity of 7.88% and a net margin of 3.33%.Envista’s revenue was up 7.1% on a year-over-year basis. During the same period last year, the business posted $0.26 earnings per share. Envista has set its FY 2026 guidance at 1.500-1.550 EPS. On average, equities analysts predict that Envista will post 1.53 earnings per share for the current year.
Envista Company Profile
Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.
Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.
Featured Stories
- Five stocks we like better than Envista
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.
